D Koschel, C Ninck Weber, G Höffken
Index: J. Investig. Allergol. Clin. Immunol. 23(4) , 275-80, (2013)
Full Text: HTML
The use of selective cyclooxygenase (COX) 2 inhibitors as an alternative to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been suggested for patients with aspirin-exacerbated respiratory disease (AERD).To evaluate tolerability to etoricoxib, a second-generation COX-2 inhibitor with high in vitro selectivity for COX-2 in patients with AERD.We conducted a retrospective review of patients with suspected aspirin intolerance seen between October 2007 and April 2012. Single-blind, placebo-controlled oral challenges with increasing doses of aspirin and etoricoxib were performed on 3 different days.Of 262 patients with suspected aspirin intolerance, 248 underwent challenge testing with aspirin and 122 (49.2%) showed positive test results. In 104 of these aspirin-sensitive patients, etoricoxib was tested as an alternative drug and was tolerated in all but 3 (2.9%), who developed a positive asthmatic reaction.The highly selective COX-2 inhibitor etoricoxib was tolerated in most but not all patients tested. An oral provocation test is therefore recommended before prescribing etoricoxib for patients with AERD.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
etoricoxib
CAS:202409-33-4 |
C18H15ClN2O2S |
Analgesic activity of Eugenia jambolana leave constituent: a...
2014-08-01 [Pharm. Biol. 52(8) , 1069-78, (2014)] |
Downregulation of NF-κB and PCNA in the regulatory pathways ...
2012-10-01 [Mol. Cell Biochem. 369(1-2) , 75-86, (2012)] |
Angiostatic role of the selective cyclooxygenase-2 inhibitor...
2012-09-01 [Biomed. Pharmacother. 66(6) , 474-83, (2012)] |
Evaluation of a single preoperative dose of etoricoxib for p...
2012-12-01 [Acta Orthop. 83(6) , 642-7, (2012)] |
Nuclear factor kappa B: a pro-inflammatory, transcription fa...
2012-01-01 [J. Environ. Pathol. Toxicol. Oncol. 31(1) , 27-37, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved